Gilead Sciences (NASDAQ: GILD) stock has been a standout among biotech companies over the past year, with its shares up more than 36%. Over the past decade, its shares delivered a total return of a little more than 131%, which means if you had invested $461,000 in the stock in 2013, you would be a millionaire now.

There's plenty of opportunity for continued growth, and here are five reasons the stock could help you become a millionaire.

Fourth-quarter sales rose 2% year over year to $7.4 billion, led by increased sales of oncology, HIV, and hepatitis C virus therapies. Earnings per share (EPS) for the quarter was $1.30 compared to $0.30 in the same period a year ago. Full-year revenue was $27.3 billion, flat compared to 2021. Full-year EPS was $3.64, down from $4.93, thanks to reduced sales of its COVID-19 therapy Veklury. 

Continue reading

Source Fool.com